Enliven Therapeutics (NASDAQ:ELVN) Reaches New 52-Week High – Time to Buy?

Enliven Therapeutics, Inc. (NASDAQ:ELVN) shares reached a new 52-week high on Monday . The stock traded as high as $57.20 and last traded at $55.7850, with a volume of 707587 shares traded. The stock had previously closed at $54.81.

Analyst Upgrades and Downgrades

ELVN has been the subject of several analyst reports. The Goldman Sachs Group increased their target price on shares of Enliven Therapeutics from $59.00 to $67.00 and gave the stock a “buy” rating in a report on Tuesday, July 21st. HC Wainwright lifted their target price on shares of Enliven Therapeutics from $56.00 to $64.00 and gave the company a “buy” rating in a research note on Thursday, July 9th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Enliven Therapeutics in a report on Friday, July 17th. Wall Street Zen upgraded Enliven Therapeutics from a “sell” rating to a “hold” rating in a research note on Monday, May 11th. Finally, JonesTrading raised their price target on Enliven Therapeutics from $45.00 to $70.00 and gave the company a “buy” rating in a report on Monday, June 29th. One investment analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $70.50.

Enliven Therapeutics Stock Performance

The stock’s fifty day moving average is $47.45 and its 200 day moving average is $39.05. The stock has a market cap of $3.72 billion, a P/E ratio of -36.59 and a beta of 0.27.

Enliven Therapeutics (NASDAQ:ELVN) last issued its quarterly earnings data on Thursday, May 7th. The company reported ($0.38) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.44) by $0.06. Equities research analysts predict that Enliven Therapeutics, Inc. will post -1.57 EPS for the current year.

Insider Activity at Enliven Therapeutics

In other Enliven Therapeutics news, Director Lori Anne Kunkel sold 10,000 shares of the business’s stock in a transaction on Monday, July 6th. The shares were sold at an average price of $50.49, for a total transaction of $504,900.00. Following the transaction, the director owned 41,884 shares in the company, valued at $2,114,723.16. The trade was a 19.27% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Benjamin Hohl sold 6,018 shares of the stock in a transaction on Friday, July 17th. The shares were sold at an average price of $52.64, for a total transaction of $316,787.52. Following the completion of the sale, the chief financial officer directly owned 46,054 shares in the company, valued at approximately $2,424,282.56. This represents a 11.56% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders have sold 32,036 shares of company stock worth $1,430,676. Corporate insiders own 3.00% of the company’s stock.

Institutional Trading of Enliven Therapeutics

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Commodore Capital LP raised its holdings in shares of Enliven Therapeutics by 0.4% in the second quarter. Commodore Capital LP now owns 4,692,809 shares of the company’s stock worth $94,138,000 after buying an additional 17,809 shares during the period. Vestal Point Capital LP grew its holdings in shares of Enliven Therapeutics by 230.2% in the fourth quarter. Vestal Point Capital LP now owns 3,830,000 shares of the company’s stock worth $58,982,000 after purchasing an additional 2,670,000 shares during the last quarter. Polar Capital Holdings Plc grew its holdings in shares of Enliven Therapeutics by 13.5% in the fourth quarter. Polar Capital Holdings Plc now owns 3,513,680 shares of the company’s stock worth $54,111,000 after purchasing an additional 418,673 shares during the last quarter. Vanguard Group Inc. increased its stake in Enliven Therapeutics by 5.9% in the 3rd quarter. Vanguard Group Inc. now owns 2,553,014 shares of the company’s stock worth $52,260,000 after buying an additional 142,378 shares during the period. Finally, State Street Corp lifted its holdings in Enliven Therapeutics by 9.1% during the 4th quarter. State Street Corp now owns 1,052,862 shares of the company’s stock valued at $16,214,000 after buying an additional 87,725 shares in the last quarter. 95.08% of the stock is owned by hedge funds and other institutional investors.

Enliven Therapeutics Company Profile

Enliven Therapeutics is a clinical-stage biotechnology company focused on developing small-molecule therapies that harness induced proximity mechanisms to selectively target and degrade disease-causing proteins in cancer. Leveraging its proprietary Induced Proximity platform, the company designs molecular glues and related modalities to recruit endogenous cellular machinery for targeted protein degradation, with the goal of treating malignancies driven by so-called “undruggable” oncogenic factors.

The company’s pipeline comprises several early-stage programs directed at key oncogenic drivers across hematologic and solid tumor indications.